Company Encyclopedia
View More
name
WAI CHUN BIOTEC
00660.HK
Wai Chun Bio-Technology Limited, an investment holding company, engages in the manufacture and sale of modified starch and other biochemical products in the People’s Republic of China. The company was formerly known as Wai Chun Mining Industry Group Company Limited and changed its name to Wai Chun Bio-Technology Limited in September 2019. The company was incorporated in 1992 and is headquartered in Wan Chai, Hong Kong.
744.65 B
00660.HKMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
C
Packaged Foods and MeatsIndustry
Industry Ranking40/50
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE17.17%A
    • Profit Margin-3.88%D
    • Gross Margin9.55%E
  • Growth ScoreC
    • Revenue YoY1.92%C
    • Net Profit YoY66.93%A
    • Total Assets YoY2.46%C
    • Net Assets YoY-13.42%E
  • Cash ScoreD
    • Cash Flow Margin-2579.28%E
    • OCF YoY1.92%C
  • Operating ScoreA
    • Turnover1.78A
  • Debt ScoreE
    • Gearing Ratio129.19%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | WAI CHUN BIOTEC funds gradually entering the market, can short-term recovery create space?

    WAI CHUN BIOTEC saw active capital entry yesterday, with its pharmaceutical defensive attributes becoming the market focus. Throughout the day, the intraday trend gently rose, and market expectations for the sector's right-side recovery increased. The approval fees for innovative drugs in the pharmaceutical industry are expected to be reduced, which has reversed the previous capital pressure and attracted short-term attention to some quality small-cap stocks. In terms of technical performance, short-term moving averages have stopped declining and are trending upwards, with increased capital accumulation at low levels. Although the main force has not expanded to an explosive level, it has significantly warmed compared to last week. The investment community is actively discussing the pharmaceutical sector's economic moat, with increased recognition of safety cushions in a volatile pattern. If the intraday trend continues to rise, there may be short-term elasticity, but high-level pressure remains, and when the sector overall slows down, chasing high prices may lead to profit-taking. During the trading session, it is essential to pay close attention to the main force's unusual movements and industry capital rotation, with operations primarily focused on buying low and selling high, and dynamic position management

    Technical Forecast·
    HK
    00660
    0.00%
    Technical Forecast·
    HK
    00660
    0.00%

    "WAI CHUN BIOTEC" narrowed its annual loss to 14.62 million yuan

    WAI CHUN BIOTEC announced its financial results for the fiscal year ending in June, with revenue recorded at HKD 377 million, an increase of 1.9% year-on-year. The loss narrowed from HKD 44.21 million in the previous year to HKD 14.62 million, with a loss per share of HKD 0.0843. No dividend is declared

    AASTOCKS·
    HK
    00660
    0.00%
    AASTOCKS·
    HK
    00660
    0.00%

    WAI CHUN BIOTEC released its annual performance, with a loss attributable to shareholders of HKD 14.623 million, a year-on-year decrease of 66.93%

    According to the Zhitong Finance APP, WAI CHUN BIOTEC announced its annual performance for the year ending June 30, 2025, with revenue of HKD 377 million, an increase of 1.92% year-on-year; the loss attributable to the company's owners was HKD 14.623 million, a decrease of 66.93% year-on-year; the loss per share was HKD 0.0843. The announcement stated that the improvement in loss was mainly due to a significant reduction in impairment losses on non-financial assets incurred during the reporting year

    Zhitong·
    HK
    00660
    0.00%
    Zhitong·
    HK
    00660
    0.00%

    "Waning Profit Warning" WAI CHUN BIOTEC forecasts a significant reduction in annual losses to HKD 13 million

    WAI CHUN BIOTEC issued a profit warning, expecting a loss of no more than HKD 13 million for the fiscal year ending in June, compared to a loss of HKD 65.7 million in the previous year. The significant reduction in loss is mainly due to a decrease in impairment losses on non-financial assets during the year

    AASTOCKS·
    HK
    00660
    0.00%
    AASTOCKS·
    HK
    00660
    0.00%

    WAI CHUN BIOTEC issued a profit warning, expecting an annual net loss not exceeding HKD 13 million, a significant decrease year-on-year

    According to the Zhitong Finance APP, WAI CHUN BIOTEC announced that the group expects to incur a net loss of no more than HKD 13 million for the year ending June 30, 2025, a significant reduction compared to the net loss of approximately HKD 65.7 million for the year ending June 30, 2024. The main reason for the substantial decrease in loss is the reduction in impairment losses on non-financial assets during the reporting year

    Zhitong·
    HK
    00660
    0.00%
    Zhitong·
    HK
    00660
    0.00%
    © 2025 Longbridge｜Disclaimer